SITC Immunotherapy for the Treatment of Multiple Myeloma 2026 Guideline – Key Recommendations
From Clinical Guideline InSights · 00:12:15
Show by Guideline Central
The 2026 Immunotherapy for the Treatment of Multiple Myeloma guideline, highlighting key recommendations across newly diagnosed multiple myeloma, toxicity management, patient education, and more. Immunotherapy for the Treatment of Multiple MyelomaSociety for Immunotherapy of Cancer (SITC)November 6, 2026Guideline Summary: https://www.guidelinecentral.com/guideline/308226/ Full-Text: https://jitc.bmj.com/content/14/11/e016142 InSights Spotlight: https://www.guidelinecentral.com/insights/nov-2026-sitc-multiplemyelomaimmunotherapytreatment-guideline-spotlight/
More episodes of Clinical Guideline InSights
More episodes
- SCAI SHOCK Stage Classification 2026 Expert Consensus Update – Key Summary Points
- AES/CNS Surgical Treatment of Epilepsy for Adults and Children 2026 Guideline - Key Recommendations
- AHA/AAP/ACOG/SMFM Female-Specific Prevention and Management of Cardiovascular Disease
- ASTRO Hypofractionated Radiation Therapy for Localized Prostate Cancer 2026 Guideline
- ATS As-Needed Inhaled Corticosteroids in Asthma 2026 Guideline – Summary of Key Recommendations
- ISH Global Hypertension Practice 2026 Guideline – Summary of 10 Key Revisions
- ASGE Management of Esophageal and Gastric Varices in Patients with Cirrhosis 2026 Guideline
- AASM Management of Shift Work Disorder 2026 Guideline - Summary of Recommendations
- ASCP/CAP HER2 Testing & Clinical Decision Making in Gastroesophageal Adenocarcinoma 2026 Guideline
- AAD/HSF Management of Hidradenitis Suppurativa 2026 Guideline - Key Recommendations
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.